Amarin investors know by now that the big news for the company will be whether its drug Vascepa gets new chemical entity, or NCE, status from the FDA, and so far, the wait has been long for an answer. In the meantime, the company is taking other measures to protect its drug from generic competition. Vascepa was just granted its ninth U.S. patent, and Amarin plans to apply for a 10th. In this video, Motley Fool analysts Max Macaluso and David Williamson discuss another factor that can give the company competitive leverage: increasing the number of suppliers it gets Vascepa's active ingredient from.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Amarin is looking at new ways to shore up its defenses against generic competition.
David Williamson owns shares of Amarin. Max Macaluso, Ph.D., has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest Smarter with The Motley Fool
Join Over Half a Million Premium Members Receiving…
- New Stock Picks Each Month
- Detailed Analysis of Companies
- Model Portfolios
- Live Streaming During Market Hours
- And Much More
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.